The current financial score of TriSalus Life Sciences Inc is 7.89. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.41M, representing a year-over-year increase of 1.73%, while its net profit experienced a year-over-year increase of 2.06%.
The current valuation score of TriSalus Life Sciences Inc is 7.15. Its current P/E ratio is -3.59, which is -100.00% below the recent high of 0.00 and -51.51% above the recent low of -5.44.
The current earnings forecast score of TriSalus Life Sciences Inc is 8.00. The average price target is 9.00, with a high of 11.00 and a low of 7.00.
The current price momentum score of TriSalus Life Sciences Inc is 4.96. Currently, the stock price is trading between the resistance level at 5.49 and the support level at 4.59, making it suitable for range-bound swing trading.
The current institutional shareholding score of TriSalus Life Sciences Inc is 3.00. The latest institutional shareholding proportion is 23.99%, representing a quarter-over-quarter increase of 19.44%.
The current risk assessment score of TriSalus Life Sciences Inc is 2.92. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.